Onkozentrum Zürich AG

What Onkozentrum Zürich AG does

Onkozentrum Zürich AG is a privately held Swiss outpatient oncology and hematology practice headquartered at Seestrasse 259, Zürich, operating across four locations in the Canton of Zürich: Zürich Enge (main site), Zürich Seefeld (shared with Hirslanden Ärztezentrum), Zürich Unterland/Bülach (via Uroviva), and Winterthur (via Zentrum für Urologie). The practice was founded in 1994–1995 and provides comprehensive cancer care including chemotherapy, immunotherapy, targeted therapies, hormone therapy, CAR-T cell therapy (CARVYKTI for multiple myeloma), high-dose chemotherapy with autologous stem cell transplantation, bispecific antibodies, and Papillon brachytherapy. Sub-specializations span gastrointestinal oncology, uro-oncology, breast and gynecological oncology, hematologic malignancies (leukemia, lymphoma, multiple myeloma), thoracic, brain, and skin tumors, supported by molecular oncology diagnostics, genetic counseling, interdisciplinary tumor boards, and psycho-oncological services.

The practice serves individual cancer patients across the full continuum from diagnosis and second opinion through treatment, survivorship, and palliative care, with a 24/7 emergency on-call oncologist. Revenue is generated through Swiss mandatory basic health insurance (KVG/LAMal) billing for outpatient services, supplemented by clinical trial participation and second opinion consultations. Effective January 2026, OZH merged with the Klinik für Hämatologie und Onkologie (KHO) and became a founding member of the newly established Hirslanden Cancer Institute, embedding the practice within Switzerland's largest private hospital network and adding inpatient oncology capacity. The leadership transitioned in 2025, with Ulf Petrausch as CEO and Daniel Helbling as Verwaltungsratspräsident (Board Chairman).

Name

Onkozentrum Zürich AG

Legal name

Onkozentrum Zürich AG

Website

https://ozh.ch

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Onkozentrum Zürich AG is a privately held Swiss outpatient oncology and hematology practice operating at four locations in Canton of Zürich, delivering comprehensive cancer care including chemotherapy, immunotherapy, CAR-T therapy, and clinical trials to individual patients across the region.

Ownership category

akta.pro rank

Product category

Outpatient Oncology Services

NAICS

Ambulatory Health Care Services (621), Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Outpatient oncology services
• Cancer treatment
• Hematology services
• Chemotherapy infusion
• Immunotherapy clinic

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Outpatient Oncology Services: Ambulatory oncology consultations, chemotherapy administration, immunotherapy, targeted therapies, and follow-up care. Revenue generated through Swiss basic and supplementary health insurance billing (KVG/LAMal).
2. Clinical Studies: Participation in clinical trials bringing access to experimental therapies while generating study-related revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Onkozentrum Zürich AG is a private, physician-led outpatient oncology and hematology center that diagnoses and treats solid tumors and hematologic malignancies across four locations in Canton of Zurich. It delivers guideline-based ambulatory cancer care, including chemotherapy, immunotherapy, antibody-drug conjugates, targeted therapy, CAR-T cell therapy, supportive/palliative care, and second-opinion consultations, and conducts clinical trials in oncology and hematology. Services are billed primarily through Swiss compulsory health insurance (OKP/KVG) and supplementary insurance.

Product overview

Onkozentrum Zürich AG operates as a multi-location outpatient oncology center in the Canton of Zurich, Switzerland, offering comprehensive cancer care across four locations (Zürich Enge, Zürich Seefeld, Zürich Unterland/Bülach, and Winterthur). The center provides a unified platform of medical oncology services including hematology, solid tumor treatment, cellular therapies (CAR-T, stem cell transplantation), immunotherapy, chemotherapy, targeted therapies, and psycho-oncology support. Key service modules include tumor board consultations for interdisciplinary case review, clinical trial access, second opinion services, genetic counseling, and molecular diagnostics. The center merged with Klinik für Hämatologie und Onkologie (KHO) in January 2026 to form the Hirslanden Cancer Institute, expanding inpatient capabilities while maintaining outpatient services across existing locations.

Differentiator

Problem solved

Functional benefit

Products and services

• Outpatient Oncology Diagnosis and Treatment Comprehensive ambulatory diagnosis, staging, and treatment of solid tumors and hematologic malignancies for adult patients in Canton of Zurich, delivered by board-certified oncologists across four locations.
• Chemotherapy and Immunotherapy Infusion Outpatient administration of chemotherapy, immunotherapy, antibody-drug conjugates, and targeted therapy in infusion suites at the four Zurich-area locations, for patients with confirmed cancer diagnoses.
• CAR-T Cell Therapy Provision of CAR-T cell therapy for eligible hematologic malignancy patients, delivered as part of the outpatient oncology offering.
• Supportive and Palliative Care Supportive and palliative care services for cancer patients during and after treatment, focused on symptom management and quality of life.
• Second Opinion Consultations Specialist oncology second opinion consultations for patients and referring physicians seeking guidance on cancer diagnosis and treatment plans.
• Oncology and Hematology Clinical Trials Participation in clinical trials for solid tumors and hematologic malignancies, giving eligible patients access to investigative therapies alongside or instead of standard care.

Quantifiable outcome

• Patient testimonials indicate successful long-term management of advanced cancers including 15+ years with prostate cancer and 9 years with esophageal cancer.
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Hirslanden Cancer InstitutecoreStrategic or Co-development Partner · 1 January 2026Onkozentrum Zürich became a founding member of the newly established Hirslanden Cancer Institute on January 1, 2026. This partnership combines the expertise of Onkozentrum Zürich with the Klinik für Hämatologie und Onkologie (KHO) to create comprehensive cancer care structures.
• Klinik für Hämatologie und Onkologie (KHO)coreStrategic or Co-development Partner · 1 January 2026Long-standing close collaboration formalized through January 2026 merger of forces. KHO is a DKG-certified cancer center providing both outpatient and inpatient care for malignant tumors and blood diseases. Many physicians from KHO have worked closely with OZH for years.
• Zentrum für Urologie WinterthurminorChannel Partner/ Reseller/ DistributorMonthly uro-oncology consultation held at the Zentrum für Urologie practice location in Winterthur's old town.
• Uroviva BülachminorChannel Partner/ Reseller/ DistributorOncology consultation and therapies offered in Uroviva Bülach building every Wednesday morning and Thursday all day.
• Klinik Hirslanden ZürichcoreImplementation/ SI/ Consulting PartnerCAR-T cell therapy and other specialized treatments requiring hospitalization are conducted at Klinik Hirslanden Zürich, one of the few certified centers in Switzerland for such procedures.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Universitätsspital Zürich, Klinik für Onkologie: University hospital oncology department within Universitätsspital Zürich, providing the full spectrum of medical oncology, hematology, cellular therapy, and clinical trials. Competes for complex cases and top oncologists in the same Zurich labor market.
• Inselspital Bern, Universitätsklinik für Medizinische Onkologie: University hospital oncology clinic at Inselspital providing comprehensive medical oncology, hematology, and cellular therapy across the Canton of Bern. Comparable breadth and academic-practice positioning within the broader Swiss market.
• Luzerner Kantonsspital (LUKS), Klinik für Medizinische Onkologie: Central Swiss cantonal hospital oncology service led by physicians such as Dr. Zander (now at OZH). Provides medical oncology, hematology, and stem cell transplant services across Canton of Lucerne.
• Charité Comprehensive Cancer Center (Berlin): DKG-certified oncology center referenced in OZH's partnership network as the German equivalent for cross-border oncology expertise. Comparable advanced-therapy scope and academic medical center footprint.
• Universitätsspital Basel, Klinik für Onkologie: University hospital oncology department at USB offering medical oncology, hematology, and clinical trials, affiliated with the University of Basel where OZH partner Prof. Renner holds a professorship. Competes for talent and Swiss referrals.

Others

• Hirslanden AG: Parent operator of the Hirslanden Cancer Institute and the broader Swiss private hospital network in which OZH is a founding member. Relevant as the institutional counterparty to OZH's 2026 integration, not as a direct outpatient competitor.
• Kantonsspital St. Gallen, Klinik für Onkologie und Hämatologie: Large cantonal hospital oncology and hematology department providing medical oncology, stem cell transplantation, and clinical trial access across Eastern Switzerland. Employer of multiple physicians who later joined OZH and a comparable regional anchor.

Direct peers

• ZeTuP Rapperswil-Jona: Private hematology/oncology practice in eastern Switzerland providing outpatient oncology, hematology, and laboratory services. Directly comparable independent-practice model in a similar Swiss regional market.
• Onkologie Bethanien: Independent outpatient medical oncology and hematology practice in the Zurich area offering diagnostics, chemotherapy, immunotherapy, and second-opinion services. Highly comparable private-practice model serving the same Canton of Zurich catchment as OZH.
• Onkologie Winterthur: Outpatient oncology practice operating in Winterthur, the same secondary city in Canton of Zurich where OZH runs a uro-oncology clinic. Closely comparable service mix and Swiss reimbursement dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/onkozentrum-z%C3%BCrich-ag

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onkozentrum Zürich AG